This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
Actions
Apr 7, 2023
Referred to the Subcommittee on Health.
Mar 27, 2023
Referred to the House Committee on Energy and Commerce.